Compare Davita Inc (DVA) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Liberty Global Ltd Class C — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Liberty Global Ltd Class C trades at $8.79 (market cap $3.06B). The key difference: Davita Inc is far larger — about 3.7× Liberty Global Ltd Class C's market cap, and Davita Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Liberty Global Ltd Class C for 21 Days on average.
| DVA | LBTYK | |
|---|---|---|
Market Cap | $11.29B | $3.06B |
Volume | 582,204 | 2,508,956 |
Sector | Health | Media |
52-Week High | $240.96 | $12.67 |
52-Week Low | $103.87 | $8.75 |
Typical Hold Time | 113 Days | 21 Days |
Enterprise Value | $24.01B | $9.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
LBTYK is trading at $8.92, down 0.28% on the day, and is near its 52-week low. The stock shows a bearish technical trend with mixed earnings, including a recent Q1 2026 beat but a Q2 2026 miss. Financially, it has a negative net income margin of -62.14% for 2026, though revenue remains stable at $4.9B. Recent news highlights strategic moves like the Ziggo Group spin-off planned for 2027 and an AI partnership to enhance customer experiences.
The outlook is cautious; while analyst consensus is bullish with a $12.67 price target, high losses and bearish technicals pose risks. Upside potential hinges on successful asset monetization and the Ziggo listing, but investors face volatility from ongoing profitability challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
